Clinical Trial Update: POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST [Phase 2]

View source ↗

Summary

A Phase 2 trial (POETIG) is evaluating ponatinib for imatinib-resistant gastrointestinal stromal tumors with KIT mutations, including exon 13 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Sponsor: Sebastian Bauer | Conditions: GIST, Malignant, KIT Exon 13 Mutation | Phase 2 | Status: UNKNOWN